Cancer Clinical Trials

Contact Cancer Clinical Trials

For more information, call 484-628-8193.

McGlinn Cancer Institute has an active clinical trials program - only the most promising treatment, prevention, and risk assessment studies are approved for our patients.

Clinical trials give our cancer patients options that reach beyond standard treatment and provide a way to discover new therapies to combat cancer.

Eligible patients have the opportunity to voluntarily participate in clinical trials.

About Clinical Trials

Clinical trials are made available to patients through our research affiliations with:

  • The Sidney Kimmel Cancer Center at Jefferson
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • National Surgical Adjuvant and Bowel Project (NSABP)
  • Radiation Treatment Oncology Group (RTOG)
  • Gynecologic Oncology Group (GOG)
  • Eastern Cooperative Oncology Group (ECOG)
  • The American College of Surgeons Oncology Group (ACoSOG)

Institutional Review Board

All clinical trials approved for our patients are carefully reviewed by our Institutional Review Board (IRB). This committee reviews and approves all clinical research that takes place at Reading Hospital.

The IRB's purpose is to ensure patient rights and safety; Federal Regulations, State Law and Hospital Policy guide the decisions of the IRB.

The IRB is a group made up of 16 members of varying backgrounds including representatives from the medical staff, chaplaincy services, nursing, pharmacy, administration, and the community. The IRB meets monthly to review new research proposals and ongoing studies.

Current Cancer Clinical Trials

Cancer clinical trials are under the direction of Terrence P. Cescon, MD, Principal Investigator. Sub-Investigators are:

  • Medical Oncoloy: Nicole M. Agostino, DO; Patrick J. Colarusso, DO; Daniel A. Forman, DO; Nick C. Leasure, MD; David M. Lu, MD; Simi M. Rai, MD; Erik J. Rupard, MD
  • Gynecologic Oncology: Bernice Robinson-Bennett, MD; John B. Villeneuve, MD
  • Radiation Oncology: Michael L. Haas, MD; Colin T. Murphy, MD; Adam J. T. Smith, MD, PhD

To learn more about any of the Cancer Clinical Trials contact the Protocol Office at 484-628-8193.

Brain

Alliance-N0577: Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

This study has been developed to treat people with anaplastic or low-grade glioma brain tumors which are positive for (contain) the 1p/19q co-deletion and IDH tumor markers.


Learn more about the Alliance-N0577 trial or call the Protocol Office at 484-628-8193.


TJU-16D.651:
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery: A Phase II Study

This is a study to evaluate the impact of radiosurgery on neurological function, particularly short-term memory.

Learn more about TJU-16D.651 trial or call the Protocol Office at 484-628-8193.

Breast

John Hopkins-J15212: Phase II Trial of Palbociclib with Fulvestrant in individuals with hormone receptor-positive, HER2-negative metastatic breast cancer who have progressed on treatment with Palbociclib and an aromatase inhibitor.

The purpose of this study is to look at the role of continuing palbociclib treatment in combination with another type of hormonal therapy after disease progression.

Learn more about the John Hopkins- J15212 trial or call the Protocol office at 484-628-8193.


NRG-BR005: This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II- IIIA breast cancer undergoing breast conserving surgery. Tumor tissue collected from biopsy before surgery may help to check if chemotherapy destroyed the breast cancer cells and may be compared to the tumor removed during surgery to check if they are the same.

The purpose of this study is to look at tumor tissue collected from a biopsy done before breast surgery to check if the chemotherapy that patients received destroyed their breast cancer cells.

Learn more about the NRG- BR005 trial or call the Protocol Office at 484-628-8193.


Alliance- A221505: A randomized trial of hypofractionated post mastectomy radiation with breast reconstruction.

The purpose of this study is to determine whether a short course radiation therapy option (3 to 4 weeks) after mastectomy is as safe and effective in the setting of breast reconstruction as the usual 5 to 6 week treatment course.

Learn more about the Alliance- A221505 trial or call the Protocol Office at 484-628-8193.


• ADJUVANT (therapy that is given in addition to the primary or initial therapy to maximize its effectiveness)

NRG-BR003: A randomized Phase III trial of adjuvant therapy comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative triple-negative invasive breast cancer

The purpose of this study is to compare the good and bad effects of the chemotherapy drug carboplatin given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin.

Learn more about the NRG-BR003 trial or call the Protocol Office at 484-628-8193.


PrECOG-PrE0109: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

The purpose of this study is to compare any good and bad effects of taking two years of Palbociclib in combination with standard anti-hormone therapy to using standard anti-hormone therapy alone and to evaluate the likelihood of invasive breast cancer returning.

Learn more about the PrECOG-PrE0109 trial or call the Protocol Office at 484-628-8193.


NSABP-B51/RTOG 1304: A randomized phase III clinical trial evaluating post-mastectomy chest wall and regional nodal XRT and post-lumpectomy regional nodal XRTin patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy

The purpose of this clinical trial is to study women who have cancer cells in their lymph nodes at the time that the breast cancer is diagnosed and then have chemotherapy before surgery that clears the cancer cells from the lymph nodes. Following surgery, radiation to the breast and lymph nodes will be evaluated against radiation to the breast only.

Learn more about the NSABP-B51/RTOG 1304 trial or call the Protocol Office at 484-628-8193.



• ADVANCED CANCER

RTOG-1119: Phase II randomized study of whole brain radiotherapy in combination with concurrent lapatinib in patients with brain metastasis from Her2-positive breast cancer

The purpose of this study is to compare the effects of adding lapatinib to standard brain radiation therapy. The study will try to find out whether radiation therapy alone or lapatinib plus radiation therapy is better at safely improving tumor control.

Learn more about the RTOG-1119 trial or call the Protocol Office at 484-628-8193.


NRG-BR002: A phase IIR/III trial of standard of care with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligo metastatic breast cancer

The purpose of this study is to test whether treating breast cancer metastases with surgery or high-dose radiation improves survival.

Learn more about the NRG-BR002
trial or call the Protocol Office at 484-628-8193



• NEOADJUVANT (therapy given before the main treatment)/ADJUVANT (therapy that is given in addition to the primary or initial therapy to maximize its effectiveness)

SWOG-S1418/BR006: A randomized phase III trial to evaluate the efficacy and safety of MK-3475 (pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer with > 1cm residual invasive cancer or positive lymph nodes (YPN+) after neoadjuvant

The purpose of this study is to compare the usual approach (i.e. no more treatment or additional post-operative chemotherapy), to any effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) after surgery.

Learn more about the SWOG-S1418/BR006 trial or call the Protocol Office at 484-628-8193


NRG-NSABP B55: A randomized, double-blinded, parallel group, placebo-controlled multi-center phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with GERMLINE BRCA1/2 mutations and high risk her2-negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

The purpose of this study is to compare the addition of olaparib after the usual treatment of chemotherapy, surgery, and radiation for a certain subset of breast cancer patients.

Learn more about the NRG-NSABP B55 trial or call the Protocol Office at 484-628-8193.

Gastrointestinal

• ANAL

ECOG/ACRIN-EA2165:
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

The purpose of this study is to find if adding the study drug, nivolumab (also known as OPDIVO®), after standard chemotherapy {(mitomycin-C and 5-fluorouracil (5-FU) or capecitabine) or 5-FU and cisplatin} and radiation will prevent the anal cancer from returning.

Learn more about the ECOG/ACRIN-EA2165 trial or call the Protocol Office at 484-628-8193.


• COLON/RECTAL


Alliance-A021502: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

The purpose of this study is to compare any good and bad effects of using the drug atezolizumab along with the usual chemotherapy compared to the usual chemotherapy alone.

Learn more about the Alliance-A021502 trial or call the Protocol Office at 484-628-8193.


NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

The purpose of this study is to learn if adding an experimental drug, pembrolizumab (also known as MK-3475), to a usual treatment is better than the usual treatment alone.

Learn more about the NRG-GI002 trial or call the Protocol Office at 484-628-8193.


NRG-GI004: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer.

The purpose of this study is to learn if adding an experimental drug, atezolizumab (MPDL3280A), to a usual treatment or giving the experimental drug alone is better than the usual treatment alone.

Learn more about the NRG-GI004 trial or call the Protocol Office at 484-628-8193.


SWOG- S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification

The purpose of this screening step is to perform a genetic test on your colorectal cancer tumor sample to see if it has a HER-2 gene amplification.

Learn more about the SWOG-S1613 trial or call the Protocol Office at 484-628-8193.


• PANCREAS

Alliance-A021501: Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

The purpose of this study is to compare any good and bad effects of using chemotherapy compared to chemotherapy and radiation prior to surgery.

Learn more about the Alliance-A021501 trial or call the Protocol Office at 484-628-8193.

Genitourinary

• BLADDER

Alliance-A031501:
A Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation

The purpose of this study is to compare any good and bad effects of using a drug called MK-3475 (pembrolizumab) after the removal of your muscle invasive bladder cancer. MK-3475 is a drug that uses a person’s own immune system to treat cancer.

Learn more about Alliance-A031501 trial or call the Protocol Office at 484-628-8193.


• PROSTATE

ECOG/ACRIN-EA8153: Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: the CHAARTED2 TrialCancer Previously Treated with Docetaxel

The purpose of this research study is to compare any good or bad effects of using the chemotherapy drug cabazitaxel (also known as Jevtana®) with the usual approach of the hormone based therapy abiraterone acetate (also known as Zytiga®) in combination with prednisone on patients with advanced prostate cancer that have already undergone treatment with hormone therapy and the chemotherapy drug docetaxel.

Learn more about the ECOG/ACRIN-EA8153 trial or call the Protocol Office at 484-628-8193.


NRG-GU002:
Phase II-III trial of adjuvant radiotherapy and androgen deprivation following radical prostatectomy with or without adjuvant docetaxel

The purpose of this study is to compare any good and bad effects of using docetaxel along with the radiation therapy and hormone suppression therapy to using radiation and hormone suppression therapy alone in men with a high chance of prostate cancer recurrence after surgically removing the prostate.

Learn more about the NRG-GU002 trial or call the Protocol Office at 484-628-8193.


NRG-GU005: Phase III IGRT and SBRT vs IGRT and hypofractionated IMRT for localized intermediate risk prostate cancer.

The purpose of this study is to compare any good and bad effects of using stereotactic body radiation therapy (SBRT), a technique that gives treatment in a shorter amount of time compared to the usual radiation therapy.

Learn more about the NRG-GU005 trial or call the Protocol Office at 484-628-8193.


NRG-GU006:
This phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with stage III-IV prostate cancer.

The purpose of this study is to compare any good and bad effects of using the drug apalutamide (study drug) along with usual radiation therapy to using usual radiation therapy alone.

Learn more about the NRG-GU006 trial or call the Protocol Office at 484-628-8193.


RTOG-0924:
Androgen deprivation therapy and high dose radiotherapy with or without whole-pelvic radiotherapy in unfavorable intermediate or favorable high risk prostate cancer: a phase II randomized trial

The purpose of this study is to compare the effects of hormone therapy (androgen deprivation) and radiation therapy to the prostate gland and seminal vesicles with hormone therapy and radiation therapy to the patient’s whole pelvic body area and the prostate cancer to find out which is better.

Learn more about the RTOG-0924 trial or call the Protocol Office at 484-628-8193.


TJU-17C.072: Prostate cancer outcomes: An international registry to improve outcomes in men with advanced prostate cancer (IRONMAN)

The purpose of this study is learn more about prostate cancer and to describe the use of different therapies for advanced prostate cancer internationally.

Learn more about the TJU-17C.072 trial or call the Protocol Office at 484-628-8193.


• RENAL

ECOG/ACRIN-EA8143:
A phase 3 randomized study comparing perioperative nivolumab vs observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC)

The purpose of this study is to compare good and bad results of adding the drug nivolumab before and after surgery to remove the kidney to the usual approach of surgically removing the kidney followed by standard postoperative follow-up and monitoring. Nivolumab may stimulate the immune system to attack any cancer cells remaining after surgery.

Learn more about the ECOG/ACRIN-EA8143 trial or call the Protocol Office at 484-628-8193.

Gynecologic

• CERVIX

NRG-GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.

The purpose of this study is to compare any good or bad effects of adding triapine to the usual cisplatin chemotherapy and radiation therapy, compared to using cisplatin chemotherapy and radiation therapy alone.

Learn more about the NRG-GY006 trial or call the Protocol Office at 484-628-8193.


RTOG-0724:
Phase III randomized study of concurrent chemotherapy and pelvic radiation therapy with or without adjuvant chemotherapy in high-risk patients with early-stage cervical carcinoma following radical hysterectomy.

The purpose of this study is to compare the effects, good and/or bad, of giving additional chemotherapy after the usual treatment of chemotherapy and radiation for cervical cancer. The standard treatment for this type of cervical cancer is cisplatin chemotherapy plus radiation. The study will determine whether adding chemotherapy with carboplatin and paclitaxel (experimental for this type of cervical cancer) to standard radiation and cisplatin chemotherapy improves survival without increasing side effects.

Learn more about the RTOG-0724 trial or call the Protocol Office at 484-628-8193.


GOG-0263: Randomized phase III clinical trial of adjuvant radiation versus chemo-radiation in intermediate risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy

The purpose of this study is to determine if weekly chemotherapy with cisplatin and simultaneous radiation therapy increases disease-free time compared to radiation therapy alone.

Learn more about the GOG-0263 trial or call the Protocol Office at 484-628-8193.


• ENDOMETRIUM

GOG-0238: A randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus

The main purpose of this study is to compare radiation therapy in combination with weekly treatment with the chemotherapy drug cisplatin to radiation therapy alone (standard treatment) for this type of cancer.

Learn more about the GOG-0238 trial or call the Protocol Office at 484-628-8193.


NRG-GY012: A Four Arm Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, the Combination of Cediranib/Olaparib and the Combination of Olaparib/Wee1 Inhibitor AZD1775 in Women With Recurrent, Persistent or Metastatic Endometrial Cancer (EEC)

The purpose of this study is to compare any good and bad effects of using experimental study drugs cediranib alone, olaparib alone, or a combination of cediranib and olaparib.

Learn more about the NRG-GY012 trial or contact the Protocol Office at 484-628-8193.


• OVARY

NRG- GY009:
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer

The purpose of this study is to compare any good and bad effects of adding Atezolizumab to the usual chemotherapy (liposomal doxorubicin) and to the usual chemotherapy with bevacizumab.

Learn more about the NRG-GY009 trial or contact the Protocol Office at 484-628-8193.

Head and Neck

ECOG/ACRIN-EA3132: Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing

This is a study to evaluate treatment after surgery for head and neck cancer. The purpose of this study is to compare two treatment approaches that are currently used after surgery for head and neck cancer.

Learn more about the ECOG/ACRIN- EA3132 trial or contact the Protocol Office at 484-628-8193.


NRG-HN001:
Randomized phase II and phase III studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA)

This study is being done to see how people with this type of cancer respond to different types or levels of chemotherapy, based on a specific viral marker in their blood. This viral marker is called the Epstein Barr virus, (EBV). A more individualized approach to treating this type of cancer might be found using this blood marker.

Learn more about the NRG-HN001 trial or contact the Protocol Office at 484-628-8193

Hematologic

• LYMPHOMA

SWOG-S1608:
A Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

The purpose of this study is to compare any good and bad effects of using different drugs in combination with an antibody.

Learn more about the SWOG-S1608 trial or contact the Protocol Office at 484-628-8193.


• MANTEL CELL LYMPHOMA

PrECOG-0404:
A Phase I/II Study of Ixazomib and Ibrutinib in relapsed/ refractory mantle cell lymphoma

The purpose of this study is to see whether the addition of ixazomib to ibrutinib chemotherapy is effective in treating people who have relapsed or refractory mantle cell lymphoma and to examine the side effects associated with ixazomib in combination with ibrutinib.

Learn more about the PrECOG-0404 trial or contact the Protocol Office at 484-628-8193.


• MYELOMA

ECOG-E1A11: Randomized phase III trial of bortezomib, lenalidomide and dexamethasone (VRD) versus carfilzomib, lenalidomide, dexamethasone (CRD) followed by limited or indefinite lenalidomide maintenance in patients with newly diagnosed symptomatic multiple myeloma

The purpose of the first part of the study is to compare the effects, good and/or bad, of a combination of carfilzomib, lenalidomide and dexamethasone with another combination of bortezomib, lenalidomide and dexamethasone, to find out which is better. The second part of the study will examine if it is better to continue lenalidomide until the myeloma comes back or limit it for a defined period of two years.

Learn more about the ECOG-E1A11 trial or contact the Protocol Office at 484-628-8193.


TJU OP-103: Randomized , controlled, open-label, Phase 3 study of Melflufen/Dexamethasone compared with pomalidomide/dexamethasone for patients with relapsed refractory multiple myeloma who are refractory to lenalidomide.

The purpose of the study is to compare melflufen + dexamethasone to pomalidomide + dexamethasone for the treatment of multiple myeloma (MM).

Learn more about TJU OP-103 trial or contact the Protocol Office at 484-628-8193.

Lung

Alliance-A151216: Adjuvant Lung Cancer enrichment marker identification and sequencing trial (Alchemist)

The purpose of the study is to examine lung cancer patients’ surgically removed tumors for certain genetic changes, and to possibly refer these patients to a treatment study with the drugs that may specifically target tumors that have the genetic changes.

Learn more about Alliance-A151216 trial or contact the Protocol Office at 484-628-8193.


• NON-SMALL CELL


TJU-BR.31: A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Learn more about the TJU-BR.31 trial or contact the Protocol Office at 484-628-8193.


NRG-LU002: Maintenance systemic therapy versus consolidative stereotactic body radiation therapy (SBRT) plus maintenance systemic therapy for limited metastatic non- small cell lung cancer (NSCLC); A Randomized Phase II/III Trial.

The purpose of this study is to compare any good and bad effects if using the usual drug therapy plus radiation to treat the lung cancer and the areas of metastasis (where the cancer has spread) compared with the usual drug therapy alone.

Learn more about the NRG-LU002 trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EA5142: Adjuvant nivolumab in resected lung cancers (anvil)- A randomized phase III study if nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancers.

The purpose of this study is to find if adding the study drug, nivolumab (also known as OPDIVO), will limit lung cancer from growing back in patients with early stage non -small cell lung cancer.

Learn more about the ECOG/ACRIN-EA5142 trial or contact the Protocol Office at 484-628-8193.


Alliance-A081105: Erlotinib hydrochloride in treating patients with stage IB- IIIA non- small cell lung cancer that has been completely removed by surgery (an Alchemist Treatment Trial)

The purpose of this study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug).

Learn more about Alliance-A081105 trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN E4512: Crizotinib in treating patients with stage IB-IIIA non- small cell lung cancer that has been removed by surgery and alk fusion mutations (an Alchemist Treatment Trial)

The purpose of this study is to compare any good and bad effect of using the study drug, crizotinib (also known as Xalkori), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK- positive non-small cell lung cancer.

Learn more about ECOG/ACRIN E4512 trial or contact the Protocol Office at 484-628-8193


• SMALL CELL

ECOG/ ACRIN EA5161: Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)

The purpose of this research study is to compare any good and bad effects of using nivolumab (OPDIVO®) along with the usual chemotherapy regimen of cisplatin/carboplatin and etoposide to using the usual chemotherapy approach alone.

Learn more about the ECOG/ACRIN EA5161 trial or contact the Protocol Office at 484-628-8193.

Melanoma

SWOG-S1320: Randomized Phase II trial of intermittent versus continuous dosing if Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant melanoma.

The purpose of this study is to compare any good and bad effects of receiving the drugs dabrafenib and trametinib continuously to receiving dabrafenib and trametinib with a break in treatment.

Learn more about SWOG-S1320 trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EA6134:
A randomized phase III trial of dabrafenib + trametinib followed by ipilmumab + nivolumab at progression vs. ipilmumab + nivolumab followed by dabrafenib + trametinib at progression in patients with advanced BRAFV600 mutant melanoma

The purpose of this research study is to compare the good and bad effects of immunotherapy followed by BRAF inhibitor therapy when the disease becomes resistant to BRAF inhibitor therapy followed by immunotherapy.

Learn more about the ECOG/ACRIN-EA6134 trial or contact the Protocol Office at 484-628-8193.


SWOG-S1616: A Phase II randomized study of nivolumab with ipilimumab or impilimumab alone in advanced melanoma patient’s refractory to an Anit-PD1 or Anti PD-L1 agent

The purpose of this study is to compare any good or bad effects of using the drug combination of ipilimumab and nivolumab with the use of ipilimumab alone for the treatment of advanced melanoma.

Learn more about the SWOG-1616 trial or contact the Protocol Office at 484-628-8193.

Molecular Analysis

ECOG/ACRIN-EAY131: Molecular analysis for therapy choice (MATCH)

The purpose of this screening step is to find out if your tumor cells have a gene change, or mutation targeted by one or more of the drugs used in this study. Participants in the screening study that have a gene change or mutation that matches a sub study will be asked to participate in a specific sub study.

Learn more about the ECOG/ACRIN-EAY131 trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131-F: Molecular analysis for therapy choice (MATCH): EAY131-F: Match treatment subprotocol F: Crizotinib in patients with tumors (other than adenocarcinoma of lung or ALCL) with ALK rearrangements

The purpose of this study is to test any good and bad effects of the study drug crizotinib. Crizotinib could shrink your cancer but it could also cause side effects.

Learn about ECOG/ACRIN-EAY131-F trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131-G: MOLECULAR ANALYSIS FOR THERAPY CHOICE TREATMENT (MATCH): MATCH TREATMENT SUBPROTOCOL G:
EAY131-G: PHASE II STUDY OF CRIZOTINIB IN PATIENTS WITH ROS1 TRANSLOCATIONS (OTHER THAN PATIENTS
WITH NONSMALL CELL LUNG CANCER)

The purpose of this study is to test any good and bad effects of the study drug crizotinib.

Learn more about ECOG/ACRIN-EAY131-G trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131-V: MATCH Treatment Subprotocol V: EAY131-V: Phase II Study of Sunitinib in Patients with Tumors with c-Kit Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor).

The purpose of this study is to test any good and bad effects of the study drug, Sunitinib, in patients whose cancer has genetic changes called cKIT mutations.

Learn more about the ECOG/ACRIN-EAY131-V trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131-A: MATCH Treatment Subprotocol A – EAY131-A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment

The purpose of this study is to test any good and bad effects of the study drug Afatinib in patients whose cancer has genetic changes called EGFR mutations.

Learn more about the ECOG/ACRIN-EAY131-A trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131-E: Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol E: EAY131-E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR

The purpose of this study is to test any good and bad effects of the study drug called AZD9291.

Learn more about the ECOG/ACRIN-EAY131-E trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131-S2: MATCH Treatment Subprotocol S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations

The purpose of this study is to test any good and bad effects of the study drug called Trametinib in patients whose cancer has GNAQ or GNA11 mutations.

Learn more about ECOG/ACRIN-EAY131-S2 trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131-T: MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations

The purpose of this study is to test any good and bad effects of the study drug GDC-0449 (vismodegib) in patients whose cancer has genetic changes in the genes Smoothened and Patched 1.

Learn more about the ECOG/ACRIN-EAY131-T trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131-C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion

The purpose of this study is to test any good and bad effects of the study drug called crizotinib. Crizotinib could shrink your cancer but it could also cause side effects.

Learn more about the ECOG/ACRIN-EAY131-C2 trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification.

The purpose of this study is to test any good and bad effects of the study drugs Trastuzumab and Pertuzumab in patients whose cancer has HER2 amplification.

Learn more about the ECOG/ACRIN-EAY131-J trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with MTOR Mutations

The purpose of this study is to test any good and bad effects of the study drug MLN0128 (TAK-228) in patients whose cancer has mTOR alterations.

Learn more about the ECOG/ACRIN-EAY131-L trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations

The purpose of this study is to test any good and bad effects of the study drug MLN0128 (TAK-228) in patients whose cancer has TSC1/2 alterations.

Learn more about the ECOG/ACRIN- EAY131-M trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions

The purpose of this study is to test any good and bad effects of the study drug LOXO-101 in patients whose cancer has NTRK fusions, involving a gene called NTRK1, NTRK2, or NTRK3. LOXO-101 could shrink your cancer but it could also cause side effects.

Learn more about the ECOG/ACRIN-EAY131-Z1E trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN- EAY131- K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Amplifications

The purpose of this study is to test any good and bad effects of the study drug (JNJ-42756493 (erdafitinib)) in patients whose cancer has FGFR Amplification. JNJ-42756493 (erdafitinib) could shrink your cancer but it could also cause side effects.

Learn more about the ECOG/ACRIN- EAY131-K1 trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131- K2: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions

The purpose of this study is to test any good and bad effects of the study drug (JNJ-42756493 (erdafitinib) in patients whose cancer has FGFR mutations or fusions. JNJ-42756493 (erdafitinib) is not approved by the Food and Drug Administration (FDA) and is currently studied in several clinical trials in the United States and other countries.

Learn more about the ECOG/ACRIN-EAY131- K2 trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131-Z1H: Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC

The purpose of this study is to test any good and bad effects of the study drug copanlisib in patients whose cancer has PTEN loss.

Learn more about the ECOG/ACRIN-EAY131-Z1H trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131-Z1F: Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed)

The purpose of this study is to test any good and bad effects of the study drug called copanlisib in patients whose cancer has PI3 kinase genetic changes.

Learn more about the ECOG/ACRIN-EAY131-Z1F trial or call the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131-Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result

The purpose of this study is to test any good and bad effects of the study drug copanlisib in patients whose cancer has PTEN loss.

Learn more about the ECOG/ACRIN-EAY131-Z1G trial or call the Protocol Office at 484-628-8193.

Non-Treatment Protocols

TJU-17F.394 Yang: A population-based approach to single CTC analysis in metastatic breast cancer outcome

We hope to use this information to find out the useful markers and apply them in the clinical setting in the future to improve the prognosis (outcome) of breast cancer patients. These analyses will not be done in real time, so the results of these markers will not affect, or influence, your current course of treatment, but participation in this research will be very helpful to better understand how to help other people with the same disease.

Learn more about the TJU-17F.394 registry or contact her Protocol Office at 484-628-8193.


• CANCER CONTROL


TJU-08D.213: Jefferson Pancreas Tumor Registry (JPTR)

The purpose of this research study is to collect information to determine if pancreas tumors and related conditions tend to occur more frequently in families with a history of the disease and to determine environmental and occupational risk factors to which patients may be exposed.

Learn more about the TJU-08D.213 trial by calling the Protocol Office at 484-628-8193.



• REGISTRY

CARIS-TCREG00100V21209: Registry of CARIS Life Sciences® Molecular Intelligence™ Service (biomarker assessment results intended for correlation with cancer clinical outcomes)

The purpose of this research registry is to evaluate your clinical outcomes, and to possibly determine which treatments may be more effective. The registry outcome data will hopefully result in a change in disease treatment and an improvement of care.

Learn more about the CARIS-TCREG00100V21209 trial by calling the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131: Molecular analysis for therapy choice (MATCH)

The purpose of this screening step is to find out if your tumor cells have a gene change, or mutation targeted by one or more of the drugs used in this study. Participants in the screening study that have a gene change or mutation that matches a sub study will be asked to participate in a specific sub study.

Learn more about the ECOG/ACRIN-EAY131 trial or contact the Protocol Office at 484-628-8193.


Johns Hopkins-TBCRC 040: Plasma tumor DNA and pathologic complete response in early-stage, high-risk breast cancer

The purpose of this study is to see if it is possible to use blood samples to predict response to treatment in breast cancer patients receiving preoperative (or neoadjuvant) therapy.

Learn more about the Johns Hopkins-TBCRC 040 trial or contact the Protocol Office at 484-628-8193.


TJU-17C.072 Ironman: Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN)

The purpose of this study is to learn more about the prostate cancer and to describe the use of different therapies for advanced prostate cancer internationally; to describe specific treatment patterns and whether they are associated with differences in outcomes such as hospitalizations; to identify associations between treatment sequences or combinations and overall survival; to define the patient experience of men with advanced prostate cancer and identify unmet needs in their treatment; to identify clinical and molecular disease subtypes that may predict for a reduction in cancer from individual treatments, combinations, or sequences.

Learn more about the TJU-17C.072 Ironman registry or contact her Protocol Office at 484-628-8193.


• RISK ASSESSMENT

CITY OF HOPE-RA-COH 96144: Molecular genetics studies of cancer patients and their relatives

The purpose of this study is to investigate genetic, biologic and behavioral factors that may contribute to the development of specific cancers and to study how these factors affect the outcome of the disease.

Learn more about the City of Hope-RA-COH 96144 trial by calling the Protocol Office at 484-628-8193.



• TRANSLATIONAL RESEARCH

NRG-BR005: This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving surgery. Tumor tissue collected from biopsy before surgery may help to check if chemotherapy destroyed the breast cancer cells and may be compared to the tumor removed during surgery to check if they are the same.

The purpose of this study is to look at tumor tissue collected from a biopsy done before breast surgery to check if the chemotherapy that patients received destroyed their breast cancer cells.

Learn more about the NRG-BR005 trial or contact the Protocol Office at 484-628-8193.


Alliance-A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

The purpose of this research study is to examine lung cancer patients’ surgically removed tumors for certain genetic changes, and to possibly refer these patients to a treatment study with drugs that may specifically target tumors that have these genetic changes.

Learn more about the Alliance-A151216 trial or contact the Protocol Office at 484-628-8193.